Pacira BioSciences
Pacira BioSciences, Inc., a leading innovator in the biopharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in advancing non-opioid pain management solutions, primarily through its flagship product, EXPAREL. This unique formulation of bupivacaine offers extended pain relief while minimising the reliance on opioids, addressing a critical need in postoperative care. With a strong presence across North America and expanding operations in international markets, Pacira BioSciences has established itself as a key player in the field of analgesia. The company’s commitment to improving patient outcomes and enhancing recovery experiences has garnered recognition, positioning it as a trusted name in pain management. Through continuous innovation and a focus on patient-centric solutions, Pacira BioSciences remains at the forefront of transforming the landscape of pain management therapies.
DitchCarbon Score
How does Pacira BioSciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pacira BioSciences's score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pacira BioSciences's reported carbon emissions
Pacira BioSciences, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. While Pacira BioSciences has not disclosed specific targets or commitments, the industry trend indicates a growing emphasis on reducing carbon footprints and enhancing environmental responsibility. As the company progresses, it may adopt industry-standard climate strategies and set measurable targets to align with global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pacira BioSciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
